Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Although all patients with cancer-associated thrombosis (CAT) have a high morbidity and
mortality risk, certain groups of patients are particularly vulnerable. This may expose the …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Background: Consensus statements have recommended against the use of direct oral
anticoagulants (DOACs) in venous thromboembolism (VTE) for patients≥ 120 kg and≥ 40 …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …

Direct oral anticoagulants (DOACs) have been a welcome addition to clinical practice due to
the practical advantages they confer over traditional anticoagulants. In many countries …

Introduction Impact of demographics and socioeconomic status (SES) on anticoagulant
treatment outcomes among patients with venous thromboembolism (VTE) is not well …